BioVaxys Co-Founder, President - GuruFocus.com
GuruFocus Article or News written by PRNewswire and the topic is about:
Source: gurufocus.com
Corporate Development Partner News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Corporate Development Partner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Corporate Development Partner Today - Breaking & Trending Today
Can immune cell-based therapies become mainstream in oncology?
20 May 2021 Can gene editing technology help transition cell-based therapies to solid tumours? Here, Jonathan Frampton looks at the potential evolution of this currently costly approach into mainstream treatment of cancer patients through the application of base editing Developing an allogeneic cell therapy is not without its challenges, including avoiding destruction by the patient’s immune system There have been two successful cell therapies that target the so called ‘liquid tumours’ (leukaemia and lymphoma). Both are chimeric antigen receptor (CAR) T cells -- Novartis’ Kymriah and...
Source: labnews.co.uk